| lopinavir/ritonavir / Generic mfg. |
INTENSE-COV, NCT04466241: Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial |
|
|
| Recruiting | 2b | 294 | RoW | Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet, LPV/r, Aluvia, Telmisartan 40Mg Oral Tablet, TMS, Micardis, Pritor, Atorvastatin 20 Mg Oral Tablet, ATV, Tahor | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS), Université de Bordeaux, PACCI Program | COVID-19, COVID-19 Drug Treatment, Severe Acute Respiratory Syndrome Coronavirus 2 | 03/21 | 03/21 | | |
2007-003896-38: PHARMACOKINETICS AND PHARMACODYNAMICS IN THE OPTIMIZATION OF ANTIRETROVIRAL TREATMENT. |
|
|
| Ongoing | 2 | 50 | Europe | Capsule, soft, Capsule, hard, Coated tablet, Tablet, KALETRA, REYATAZ, TELZIR, VIRAMUNE, SUSTIVA | AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA | Children 2-16 years old with documented vertical HIV-1 infection | | | | |
2008-006287-11: Virologic efficacy of Maraviroc in adult naive HIV patients with HIV-RNA>= 1000 copies/ml |
|
|
| Ongoing | 2 | 60 | Europe | CELSENTRI, TRUVADA, KALETRA, CELSENTRI, TRUVADA, KALETRA | OSPEDALE S. RAFFAELE | naive HIV affected patients | | | | |
2020-001892-34: Treatment of COVID-19 by Nebulization of Inteferon Beta 1b added to lopinavir/ritonavir: Feasibility, Efficiency and Safety Study Traitement du COVID-19 : Etude de faisabilité, d’efficacité et de sécurité de l’ajout de Nébubilisation d’Interferon Beta 1b au lopinavir/ritonavir |
|
|
| Not yet recruiting | 2 | 60 | Europe | Inteferon Beta 1b, lopinavir/ritonavir, NaCl, Powder and solvent for solution for injection, Coated tablet, Solution for injection, Extavia, Lopinavir/Ritonavir Mylan, NaCl | CHU Amiens-Picardie, CHU Amiens | Infection SARS-Cov-2 Infection SARS-Cov-2, covid 19 covid 19, Diseases [C] - Virus Diseases [C02] | | | | |
2020-002106-68: FLARE: Favipiravir +/- Lopinavir: A RCT of Early antivirals |
|
|
| Ongoing | 2 | 240 | Europe | Favipiravir, Lopinavir/ritonavir, Tablet, Lopinavir/ritonavir | University College London Comprehensive Clinical Trial Unit, LifeArc | SARS-CoV-2 (Corona virus) infection, COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04521400: the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19 |
|
|
| Not yet recruiting | 2 | 100 | NA | High dose Interferon-beta 1a, Lopinavir/Ritonavir, Low dose Interferon-beta 1a | Shahid Beheshti University of Medical Sciences | Covid19 | 09/20 | 09/20 | | |
2020-002314-40: A Pilot study to investigate the cardiac effect and pharmacokinetics of potential combination treatments for COVID-19 |
|
|
| Not yet recruiting | 2 | 16 | Europe | Kaletra, Ribavirin, Film-coated tablet, KALETRA - Filmtabletten 200 mg/50 mg, Ribavirin-ratiopharm® 200 mg Filmtabletten | Medizinische Universität Wien; Universitätsklinik für Klinische Pharmakologie, Medizinische Universität Wien | Healthy volunteers, Healthy volunteers, Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR-TRC-13003140: Pharmacokinetic Study of Albuvirtide and Lopinavir/Ritonavir in HIV-infected Patients |
|
|
| Completed | 1/2 | 20 | | LPV/RTV and Albuvirtide at a dose of 160mg for 46 days ;LPV/RTV and Albuvirtide at a dose of 320mg for 46 days | Beijing YouAn Hospital, Capital medical university; Frontier Biotechnologies Co., Ltd, Frontier Biotechnologies Co.,Ltd | AIDS | | | | |
NCT04390152: Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19 |
|
|
| Recruiting | 1/2 | 40 | RoW | Wharton's jelly derived Mesenchymal stem cells., Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) | BioXcellerator, Clinical Somer | Acute Respiratory Distress Syndrome | 12/21 | 04/22 | | |
NCT02140255: Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission |
|
|
| Recruiting | 1/2 | 1120 | US, RoW | Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r), Raltegravir (RAL), VRC01, DTG, VRC07-523LS | National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH) | HIV Infection | 01/28 | 12/31 | | |
